Otto Boerman
Overview
Explore the profile of Otto Boerman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
507
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Afzelius P, Heegaard P, Jensen S, Alstrup A, Schonheyder H, Eek A, et al.
Am J Nucl Med Mol Imaging
. 2020 Mar;
10(1):32-46.
PMID: 32211217
Osteomyelitis (OM) is an important cause of morbidity and sometimes mortality in children and adults. Long-term complications can be reduced when treatment is initiated in an early phase. The diagnostic...
2.
Raave R, Sandker G, Adumeau P, Jacobsen C, Mangin F, Meyer M, et al.
Eur J Nucl Med Mol Imaging
. 2019 Nov;
47(2):505-506.
PMID: 31707427
No abstract available.
3.
Joosten L, Brom M, Peeters H, Bos D, Himpe E, Bouwens L, et al.
Mol Pharm
. 2019 Jul;
16(9):4024-4030.
PMID: 31345042
Objective: Targeting the glucagon-like peptide-1 receptor with radiolabeled exendin is a very promising method to noninvasively determine the β cell mass in the pancreas, which is needed to unravel the...
4.
Raave R, Sandker G, Adumeau P, Jacobsen C, Mangin F, Meyer M, et al.
Eur J Nucl Med Mol Imaging
. 2019 Jun;
46(9):1966-1977.
PMID: 31161258
Purpose: Currently, the most commonly used chelator for labelling antibodies with Zr for immunoPET is desferrioxamine B (DFO). However, preclinical studies have shown that the limited in vivo stability of...
5.
Brom M, Joosten L, Frielink C, Peeters H, Bos D, van Zanten M, et al.
Diabetes
. 2018 Jul;
67(10):2012-2018.
PMID: 30045920
The changes in β-cell mass (BCM) during the development and progression of diabetes could potentially be measured by radionuclide imaging using radiolabeled exendin. In this study, we investigated the potential...
6.
Odenthal J, Rijpkema M, Bos D, Wagena E, Croes H, Grenman R, et al.
Sci Rep
. 2018 Jul;
8(1):10467.
PMID: 29992954
Head and neck squamous cell carcinoma (HNSCC) is an often highly invasive tumor, infiltrating functionally important tissue areas. Achieving complete tumor resection and preserving functionally relevant tissue structures depends on...
7.
Liu Y, Schouten C, Boerman O, Wu G, Jansen J, Hunziker E
J Biomed Mater Res A
. 2018 Mar;
106(9):2363-2371.
PMID: 29569828
Biomimetically deposited calcium phosphate-based coatings of prostheses can serve as a vehicle for the targeted delivery of growth factors to the local implant environment. Based on indirect evidence in previous...
8.
Joosten L, Brom M, Peeters H, Heskamp S, Behe M, Boerman O, et al.
Mol Pharm
. 2017 Dec;
15(2):486-494.
PMID: 29226686
Glucagon-like peptide-1 receptor (GLP-1R) targeting using radiolabeled exendin is a promising approach to noninvasively visualize and determine beta cell mass (BCM), which could help to unravel the pathophysiology of diabetes....
9.
Heskamp S, Raave R, Boerman O, Rijpkema M, Goncalves V, Denat F
Bioconjug Chem
. 2017 Aug;
28(9):2211-2223.
PMID: 28767228
Immuno-positron emission tomography (immunoPET) with Zr-labeled antibodies has shown great potential in cancer imaging. It can provide important information about the pharmacokinetics and tumor-targeting properties of monoclonal antibodies and may...
10.
Frigerio B, Franssen G, Luison E, Satta A, Seregni E, Colombatti M, et al.
Oncotarget
. 2017 Jan;
8(7):10919-10930.
PMID: 28051996
Purpose: In the context of prostate cancer (PCa) imaging, the aim of this study was to optimize (in vitro) the specificity and assess preclinically (in vivo) the tumor targeting properties...